消核通窍方治疗痰瘀互结型小儿腺样体肥大的临床效果

doi:10.20047/j.issn1673-7210.2023.11.20

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (644 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Xiaohe Tongqiao Prescription on adenoid hypertrophy of phlegm-stasis interjunction type in children. Methods A total of 77 adenoid hypertrophy with phlegm-stasis interjunction type in Henan Provincial Hospital of Traditional Chinese Medicine from January to December 2021 were selected, they were divided into treatment group (39 cases) and control group (38 cases) according to the random number table method. The treatment group was given Xiaohe Tongqiao Prescription, and the control group was given Mometasone Furoate Nasal Spray and Montelukast Sodium Chewable Tablet. After four weeks, the clinical efficacy, traditional Chinese medicine syndrome score, quality-of-life, adenoid volume A/N score, interleukin (IL)-4, IL-6, eosinophilic percentage (EOS%), and serum total immunoglobulin E (IgE) between two groups were compared, and adverse reactions and recurrence rates between two groups were observed. Results The clinical effect of treatment group was better than that of control group (P＜0.05). After treatment, the scores of night sleep snoring, open mouth breathing, nasal congestion, cough and sputum, sore throat, nausea, head and body sleepiness, breathing and awakening, and face of two groups were lower than those before treatment, and treatment group was lower than control group (P＜0.05). After treatment, the scores of the OSA-18 scale in both groups were lower than those before treatment, and the treatment group was lower than the control group (P＜0.05). After treatment, the scores of A/N of two groups were lower than those before treatment, and treatment group was lower than control group (P＜0.05). After treatment, the levels of IL-4 and IL-6 in both groups were lower than those before treatment, and treatment group was lower than control group (P＜0.05). After treatment, EOS% and serum total IgE in both groups were lower than those before treatment, and EOS% in treatment group was lower than that in control group (P＜0.05). Conclusion Xiaohe Tongqiao Prescription has remarkable effect on adenoid hypertrophy of phlegm-stasis interjunction type in children.

Key words： Adenoid hypertrophy Phlegm-stasis interjunction type Xiaohe Tongqiao Prescription Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIAO Shunan1 ZHU Shan2 ZHANG Ya1 LI Xinyang1

Cite this article:

QIAO Shunan1 ZHU Shan2 ZHANG Ya1 LI Xinyang1. Clinical effect of Xiaohe Tongqiao Prescription on adenoid hypertrophy of phlegm-stasis interjunction type in children[J]. 中国医药导报, 2023, 20(11): 89-93.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.11.20 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I11/89

[1] 孔维佳.耳鼻咽喉头颈外科学[M].3版.北京：人民卫生出版社，2017：227-229.
[2] 王天有，江载芳.诸福棠实用儿科学[M].9版.北京：人民卫生出版社，2022.
[3] 张钦明.孟鲁司特钠治疗儿童腺样体肥大的效果[J].医学理论与实践，2022，35（15）：2624-2625.
[4] 孙书臣，马彦，乔静，等.儿童腺样体肥大引发睡眠呼吸障碍的中医诊疗专家共识[J].世界睡眠医学杂志，2014， 1（6）：316-320，313.
[5] 李向宇.《诸病源候论》对鼾眠的认识[J].甘肃中医学院学报，2009，26（2）：16-17.
[6] 王士贞.中医耳鼻咽喉科学[M].北京：中国中医药出版社，2016：115-117.
[7] 马融.中医儿科学[M].10版.北京：中国中医药出版社，2016：34-35.
[8] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[9] 龙朝庆，颜永毅，容庆丰.OSA-18量表评估腺样体肥大儿童生活质量[J].山东大学耳鼻喉眼学报，2015，29（3）：13-15，19.
[10] 张薇，葛文彤，唐力行，等.儿童慢性鼻窦炎合并腺样体肥大菌谱及预后相关因素分析[J].中国耳鼻咽喉颅底外科杂志，2021，27（2）：151-156.
[11] 吴佳凯，韦僖文，陈宇宁.腺样体肥大儿童血清过敏原检测的临床结果分析[J].中国医药科学，2020，10（9）：148-150.
[12] 于清波.OM85-BV治疗儿童反复上呼吸道感染伴腺样体肥大的效果及对血清TNF-α、IL-6、sIL-2R水平的影响[J].中国医学创新，2022，19（4）：8-12.
[13] 张春林，林小燕，李春雷，等.胃内容物鼻咽部反流与腺样体组织免疫状态的相关性研究[J].重庆医学，2017， 46（6）：760-763.
[14] 刘燕，魏萍，寇巍，等.儿童腺样体肥大与耳鼻咽喉科常见疾病关系的研究进展[J].山东大学耳鼻喉眼学报，2019， 33（4）：149-154.
[15] 赵迪，王萌，曹志伟.腺样体肥大与变应性鼻炎的相关性研究进展[J].中国医科大学学报，2022，51（6）：543- 547.
[16] 沈子庆.非手术药物序贯治疗患儿腺样体肥大伴变应性鼻炎的效果[J].中外医学研究，2021，19（24）：15-17.
[17] 申玲，张军辉.孟鲁司特钠咀嚼片联合莫米松鼻喷雾剂对儿童型鼻窦炎合并腺样体肥大的疗效及安全性分析[J].中国合理用药探索，2020，17（7）：57-60.
[18] 袁宇，邹秀丽.孟鲁司特钠联合糠酸莫米松鼻喷雾剂治疗小儿腺样体肥大的临床疗效[J].临床合理用药杂志，2021，14（36）：138-140.
[19] 刘小会，于博然，田超，等.孟鲁司特钠致儿童药品不良反应文献的病例分析[J].中国医院用药评价与分析，2022， 22（8）：1010-1013.
[20] 林伟斌，蒋恬，王鹤潼，等.应用国医大师朱良春痰瘀互结理论治疗小儿腺样体肥大初探[J].深圳中西医结合杂志，2022，32（12）：43-45，137.
[21] 曹振锋，黄玲玲，彭韶，等.血清中IL-4、IL-6、TNF-α水平在儿童睡眠呼吸障碍中的价值[J].医药论坛杂志，2021，42（2）：65-67.
[22] 杨丽，周易，王晓明，等.炮制对半夏化学成分及药理作用研究进展[J].辽宁中医药大学学报，2022，24（2）：49- 53.
[23] 张晓娟，张燕丽，左冬冬.川芎的化学成分和药理作用研究进展[J].中医药信息，2020，37（6）：128-133.
[24] 盛永成，王晶，张世洋，等.厚朴药理研究进展[J].成都中医药大学学报，2018，41（2）：109-114.
[25] 刘传梦，陈海鹏，谭柳萍，等.苍耳子药理作用及毒性研究进展[J].中国实验方剂学杂志，2019，25（9）：207-213.